Food Allergy Diagnostic Test Response to Previous Oral Challenge Response

Completed · Not applicable

Conditions studied: Food Hypersensitivity

In brief

The objective of this study is to compare the ocular response to CAC (using food allergen sensitive patients) to the systemic response of a previously performed oral food allergen challenge in the same subjects. This study will investigate the potential utility of CAC as a predictive tool for identifying patient response to food allergen challenge and maximum tolerated dose.

Key facts

Study ID

NCT03693456

Run by

ORA, Inc.

People needed

19

Starts

2016-05-01

Expected to finish

2016-10-01

Last updated by the study team

2018-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be male or female of any race, at least 5 years of age with documented food challenge in the past 12 months;
• Have provided verbal and written informed consent. If under 18, a parent/guardian must provide consent for the subject;
• Negative pregnancy test for women of childbearing potential;
• Be willing and able to follow instructions, including participation in study assessments, and can be present for the required study visits for the duration of the study;

You may not qualify if…

• Be a woman who is pregnant or nursing an infant;
• Be unable to discontinue short-acting antihistamines for three days or long-acting antihistamines for five to seven days (depending on half-life) prior to CAC;
• Have asthma that has evolved and now fulfills any of the criteria defined as follows:
• uncontrolled persistent asthma by National Asthma Education and Prevention Program Asthma guidelines (2007) or by Global Initiative for Asthma (2011) or being treated with combination therapy of medium dose inhaled corticosteroid with a long acting inhaled β2-agonists.
• at least two systemic corticosteroid courses for asthma in the past year or one oral corticosteroid course for asthma in the past three months.
• prior intubation for asthma in the past year;
• Be receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy;
• Be receiving or planning to receive anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or any biologic immunomodulatory therapy;
• Be receiving or planning to receive any type of immunotherapy to any food (e.g. oral immunotherapy, sublingual immunotherapy, specific oral tolerance induction) during their participation in the study;
• Be receiving or planning to receive any aeroallergen immunotherapy during their participation in the study;
• Be suffering from generalized dermatologic disease (e.g. severe atopic dermatitis, uncontrolled generalized eczema, ichthyosis vulgaris);
• Have any new disorder in which epinephrine is contraindicated such as coronary artery disease, uncontrolled hypertension, or serious ventricular arrhythmias;
• Have experienced severe anaphylaxis resulting in emergency hospitalization;

Where it is running

• Allergy, Asthma & Immunology Relief (AAIR) of Charlotte — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.